A novel molecular probe 131I-K237 targeting tumor angiogenesis in human prostate cancer xenografts

Zhao,Qian; Zhang,Yu; Guo,Jun; Li,Juan

doi:10.3892/mmr.2015.3504

A novel molecular probe 131I-K237 targeting tumor angiogenesis in human prostate cancer xenografts

Authors:
- Qian Zhao
- Yu Zhang
- Jun Guo
- Juan Li
View Affiliations

Affiliations: Department of Nuclear Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China, Department of Nuclear Medicine, Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China, Department of Nuclear Medicine, Postgraduate College of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
Published online on: March 18, 2015 https://doi.org/10.3892/mmr.2015.3504
Pages: 1363-1367

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Specific molecular probes are essential for the early diagnosis of prostate cancer. In addition, peptides have been shown to have numerous uses as diagnostic and therapeutic molecular probes. The K237 peptide binds to the vascular endothelial growth factor receptor with high affinity and specificity, and was predicted to have potential use as a probe in tumor angiogenesis. The overall aim of the present study was to assess the diagnostic potential of 131I‑K237 as a molecular probe for prostate cancer. The K237 peptide was radiolabeled with 131I using an Iodogen method. The radiolabeling efficiency and radiochemical purity were found to be 73.7±3.2 and 96.7±0.6%, respectively, which were determined using thin layer chromatography and high performance liquid chromatography in vitro. Cellular uptake and competition binding experiments were used to identify the affinity of 131I‑K237 to LNCaP prostate cancer cells. The binding ratio of 131I‑K237 to LNCaP cells in the experimental group was 95.8±1.5%, whereas the binding ratios in the 5 kBq Na131I, 10 kBq Na131I, 15 kBq Na131I and PBS groups were 8.2±0.4, 8.3±0.2, 8.5±0.2 and 0.0%, respectively. In addition, the binding ratio of 131I‑K237 to LNCaP significantly decreased with the increased dose of unlabeled K237. A total of 40 male BALB/c mice with LNCaP xenografts were used for biodistribution and single photon emission computed tomography imaging analysis. An image was obtained and tumors were visible from 2 h post injection of 131I‑K237. In conclusion, the results of the present study showed that 131I‑K237 had a high affinity for LNCaP cells and may be considered as a candidate diagnostic molecular probe for prostate cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	da Silva HB, Amaral EP, Nolasco EL, et al: Dissecting major signaling pathways throughout the development of prostate cancer. Prostate cancer. 2013:9206122013. View Article : Google Scholar : PubMed/NCBI
3	Weissleder R and Pittet MJ: Imaging in the era of molecular oncology. Nature. 452:580–589. 2008. View Article : Google Scholar : PubMed/NCBI
4	Macis G, Di Giovanni S, Di Franco D and Bonomo L: Future perspectives for diagnostic imaging in urology: from anatomic and functional to molecular imaging. Urologia. 80:29–41. 2013.In Italian. View Article : Google Scholar : PubMed/NCBI
5	Wagner HN Jr: Advancing a molecular theory of disease. J Nucl Med. 49:15N–34N. 2008.PubMed/NCBI
6	Engle JW, Hong H, Zhang Y, Valdovinos HF, Myklejord DV, et al: Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody. Mol Pharm. 9:1441–1448. 2012. View Article : Google Scholar : PubMed/NCBI
7	Haubner R and Decristoforo C: Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci (Landark Ed). 14:872–886. 2009. View Article : Google Scholar
8	Liu S, Liu H, Jiang H, Xu Y, Zhang H and Cheng Z: One-step radiosynthesis of ¹⁸F-AlF-NOTA-RGD₂ for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging. 38:1732–1741. 2011. View Article : Google Scholar : PubMed/NCBI
9	Perugini M, Varelias A, Sadlon T and D’Andrea RJ: Hematopoietic growth factor mimetics: from concept to clinic. Cytokine Growth Factor Rev. 20:87–94. 2009. View Article : Google Scholar : PubMed/NCBI
10	Hetian L, Ping A, Shumei S, et al: A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem. 227:43137–43142. 2002. View Article : Google Scholar
11	Shelton PT and Jensen KJ: Linker, resins, and general procedures for solid-phase procedures for solid-phase peptide synthesis. Methods Mol Biol. 1047:23–41. 2013.
12	Salacinski RP, McLean C, Sykes JE, et al: Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent 1,3,4,6-tetrachloro-3α-6α-diphenyl glycouril (Iodogen). Anal Biochem. 117:136–146. 1981. View Article : Google Scholar : PubMed/NCBI
13	Auprich M, Bjartell A, Chun FK, et al: Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 60:1045–1054. 2011. View Article : Google Scholar : PubMed/NCBI
14	Ren J, Wang F, Wei G, et al: MRI of prostate cancer antigen expression for diagnosis and immunotherapy. PLoS One. 7:e383502012. View Article : Google Scholar
15	Mease RC, Foss CA and Pomper MG: PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 13:951–962. 2013. View Article : Google Scholar : PubMed/NCBI
16	Folkman J: Role of angiogenesis in tumor growth and metastasis. Seminars in oncology. WB Saunders. 29(6 Suppl 16): 15–18. 2002.
17	Prud’homme GJ and Glinka Y: Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget. 3:921–939. 2012.
18	Cai Y, Balli D, Ustiyan V, et al: Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis. J Biol Chem. 288:22527–22541. 2013. View Article : Google Scholar : PubMed/NCBI
19	Li R, Ren M, Chen N, et al: Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. BMC Cancer. 14:1672014. View Article : Google Scholar : PubMed/NCBI
20	Roskoski R Jr: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 63:179–213. 2007. View Article : Google Scholar
21	Dai J and Rabie AB: VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res. 86:937–950. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zheng Q, Du J, Zhang Z, et al: Association study between of Tie2/angiopoietin-2 and VEGF/KDR pathway gene polymorphisms and vascular malformations. Gene. 523:195–198. 2013. View Article : Google Scholar : PubMed/NCBI
23	Zhang YL, Wang P, Lu YY, et al: Effects of K237 on the proliferation of PC-3M cells and mRNA expressions of bax and bcl-2. Zhonghua Nan Ke Xue. 15:1098–1101. 2009.In Chinese.
24	Al-Saeedi FJ, Bitar M and Pariyani S: Effect of asiaticoside on 99mTc-tetrofosmin and 99mTc-sestamibi uptake in MCF-7 cells. J Nucl Med Technol. 39:279–283. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wang H, Xia JW, Zhang ZY, et al: Preparation of ¹³¹I-K237 and the experimental study on targeting therapy in nude mice bearing human lung cancer. Chinese J Nucl Med. 30:390–394. 2010.In Chinese.
26	Wei H, Hao X and Su M: Study on the affinity of peptides K237 with human prostate cancer cell line LNcap. Mod Oncol. 15:10–12. 2007.In Chinese.
27	Zhao Q, Yan P, Yin L, et al: Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice. Mol Med Rep. 7:1355–1360. 2013.PubMed/NCBI
28	Burnett JL and Davies AV: Investigating the time resolution of a compact multidimensional gamma-spectrometer. J Radioanal Nucl Chem. 288:699–703. 2011. View Article : Google Scholar